Borosil Scientific Limited Annual Report FY2026

Official PDF · AI Summary · Financial Analysis
Official Annual + Quarterly Filings · AI Business Intelligence
NSE: BOROSCI
Sector: Capital Goods
Industry: Glass - Industrial
Source: NSE / BSE
Last Updated: 03 Aug 2026
Business Intelligence Report Verdict
Average
Outlook: Neutral

Quality Scores

Business Compounding
64/100
Compounder
74/100
Management
82/100
Governance
88/100
Cash Flow
65/100

Latest Quarterly Earnings Summary

No quarterly summary available yet.

AI Summary

Borosil Scientific Limited, a key constituent of the Borosil Group, is a specialized player in the scientific and laboratory glassware market. The business has successfully transitioned through a restructuring phase, maintaining its leadership in QC-intensive sectors like pharmaceuticals and biotechnology. Financially, the company exhibits a stable growth trajectory with revenues increasing from ₹392 Cr to ₹467 Cr over the reported three-year cycle. While operating margins are healthy at 13%, the return on equity remains relatively modest at approximately 9.5-10%. The company maintains a…

Key Changes in FY2026

The business has evolved from a traditional glassware manufacturer into a specialized supplier for microbiology, biotechnology, and pharmaceutical quality control. A significant strategic shift occurred between FY24 and FY26, evidenced by a steady increase in sales from ₹392 Cr to ₹467 Cr and a diversification into tubular glass vials and ampoules. The company is moving up the value chain by targeting high-margin pharmaceutical customers, who now form a significant portion of the scientific customer mix. Digital transformation and increased SKU complexity suggest an evolution toward a 'one-stop-shop' for laboratory needs.

Management Commentary

The management team, deeply rooted in the Borosil Group's long heritage since 1962, demonstrates high domain expertise in the scientific glassware niche. Communication is transparent regarding the company's market position in domestic laboratory glassware and its reliance on the pharmaceutical sector. Recent management changes, such as the transition of Sharad Tiwari, appear to be internal reorganizations rather than signs of instability. The promoter holding is strong and increasing, moving from 67.8% to 68.27% over recent quarters, which signals high management conviction. However, the lack of dividend distribution despite a 'debt-free' status suggests a very conservative or perhaps cautious management outlook. Overall management quality is rated high due to the group's legacy and lack…

Financial Highlights

The business demonstrates steady top-line growth, with a TTM revenue increase of 8% and a notable profit surge of 50%, albeit from a lower base during the restructuring period. Operating Profit Margins (OPM) have shown resilience, improving from 12% in FY24 to 13% in FY26. The bottom-line quality is bolstered by consistent profits, although the tax rate has shown significant volatility ranging from 19% to 34%. Capital efficiency, measured by ROCE, has improved from 10% to 12% over three years, indicating better utilization of the capital base. The presence of significant non-operating income in FY25 (₹8 Cr) slightly inflated the profit before tax for that period. Overall, the financial profile is one of a stable industrial entity with moderate growth and high asset backing.

Major Opportunities

  • Virtually debt-free balance sheet
  • Consistent double-digit operating margins
  • Positive free cash flow generation

Major Risks

  • High inventory holding period (226 days)
  • Low historical Return on Equity (ROE)
  • Zero dividend payout despite profitability

About This Annual Report

The Borosil Scientific Limited FY2026 Annual Report is the company's flagship annual disclosure, filed with NSE / BSE. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.

Why Use AI?

  • Summarises hundreds of pages into a focused executive briefing
  • Identifies year-on-year key changes automatically
  • Extracts management commentary and tone
  • Highlights top risks and opportunities
  • Compares business evolution vs. earlier years
  • Answers your questions in plain English via Ask AI

Frequently Asked Questions

Related Research

AI Top Insights — Premium

Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.